Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038851 | 0.91 | LCK (0.69) | LCKSRC | |
| SCHEMBL4045378 | 0.90 | LCK (0.72) | LCKSRC | |
| SCHEMBL4036075 | 0.89 | LCK (0.76) | LCKSRC | |
| SCHEMBL4039580 | 0.88 | LCK (0.69) | LCKSRC | |
| SCHEMBL4038483 | 0.87 | LCK (0.75) | LCKSRC | |
| SCHEMBL4038986 | 0.87 | LCK (0.68) | LCKSRC | |
| SCHEMBL4037424 | 0.87 | LCK (0.75) | LCKSRC | |
| SCHEMBL4038195 | 0.87 | LCK (0.75) | LCKSRC | |
| SCHEMBL4039733 | 0.87 | LCK (0.75) | LCKSRC | |
| SCHEMBL4039788 | 0.87 | LCK (0.75) | LCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-2027128-A2 | FUSED HETEROCYLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | Astra Zeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007130825-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MGLUR5 MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-5990109-A | NOVEL COMPOUNDS, METHODS OF THEIR SYNTHESIS, AND THEIR USE IN TREATING VARIOUS TYROSINE KINASE-ASSOCIATED IMMUNOLOGICAL DISORDERS, SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GRAFT VS. HOST DISEASE, LUPUS, PSORIASIS AND ASTHMA | BRISTOL-MYERS SQUIBB CO. (US) | 1999-11-23 | — | — | US | disclosed |